See more : Lotus Eye Hospital and Institute Limited (LOTUSEYE.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Cyteir Therapeutics, Inc. (CYT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cyteir Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- International Consolidated Airlines Group S.A. (IAG.MC) Income Statement Analysis – Financial Results
- China Times Publishing Comp. (8923.TWO) Income Statement Analysis – Financial Results
- TPG Pace Beneficial Finance Corp. (TPGY-UN) Income Statement Analysis – Financial Results
- Encounter Resources Limited (ENR.AX) Income Statement Analysis – Financial Results
- Finolex Industries Limited (FINOLEXIND.BO) Income Statement Analysis – Financial Results
Cyteir Therapeutics, Inc. (CYT)
About Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 8.00K |
| Cost of Revenue | 1.38M | 479.00K | 351.00K | 12.69K |
| Gross Profit | -1.38M | -479.00K | -351.00K | -4.69K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | -58.61% |
| Research & Development | 34.62M | 30.96M | 16.77M | 12.77M |
| General & Administrative | 13.55M | 11.30M | 4.18M | 3.35M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.55M | 11.30M | 4.18M | 3.35M |
| Other Expenses | 2.11M | 133.00K | 120.00K | -8.00K |
| Operating Expenses | 48.17M | 42.26M | 20.94M | 16.11M |
| Cost & Expenses | 48.17M | 42.26M | 20.94M | 16.11M |
| Interest Income | 0.00 | 133.00K | 120.00K | 246.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 668.00K | 479.00K | 351.00K | 215.00K |
| EBITDA | -47.50M | -41.78M | -20.59M | -15.89M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -198,625.00% |
| Operating Income | -48.17M | -42.26M | -20.94M | -16.11M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -201,312.50% |
| Total Other Income/Expenses | 2.11M | 133.00K | 120.00K | 1.06M |
| Income Before Tax | -46.06M | -42.13M | -20.82M | -15.04M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -188,050.00% |
| Income Tax Expense | -2.11M | -479.00K | 0.00 | 0.00 |
| Net Income | -43.95M | -41.65M | -20.82M | -15.04M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -188,050.00% |
| EPS | -1.25 | -2.14 | -0.87 | -0.77 |
| EPS Diluted | -1.25 | -2.14 | -0.87 | -0.77 |
| Weighted Avg Shares Out | 35.27M | 19.50M | 23.89M | 19.43M |
| Weighted Avg Shares Out (Dil) | 35.27M | 19.50M | 23.89M | 19.43M |
Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in a fireside...
Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in a fireside...
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the second quarter ended June 30, 2022 and provided an update on...
Cyteir Therapeutics, Inc. (CYT) CEO Dr. Markus Renschler on Q4 2021 Results - Earnings Call Transcript
Cyteir Therapeutics, Inc. (CYT) CEO Dr. Markus Renschler on Q4 2021 Results - Earnings Call Transcript
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided...
Cyteir Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 16, 2022
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a conference call and live audio webcast on Wednesday, March 16, 2022 at 4:30 p.m....
Cyteir Therapeutics Selected to Join Russell 2000® Index
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer was added as a member of the U.S. small-cap Russell 2000® Index, effective after the US market...
Cyteir Therapeutics to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in a fireside chat...
Cyteir Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in the 2021 Wedbush...
Cyteir Therapeutics Announces Closing of Initial Public Offering
LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the closing of its initial public offering of 7,400,000 shares of its common stock at...
Source: https://incomestatements.info
Category: Stock Reports